Evidence map›Paper›PMID 25617494›Full record

ReviewCurrent opinion in virology2015

Reassessing immune control of hepatitis A virus.

Christopher M Walker, Zongdi Feng, Stanley M Lemon

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Hepatitis A virus infection.Nature reviews. Disease primers · 2023
    Review
  5. Review
  6. Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Review
  7. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Article
  9. Observational
  10. Review
  11. Immunization against Hepatitis A.Cold Spring Harbor perspectives in medicine · 2019
    Review
  12. Review
  13. Review
  14. Article
  15. Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A.Cold Spring Harbor perspectives in medicine · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Christopher M WalkerCenter for Vaccines and Immunity, Nationwide Children's Hospital, USA; College of Medicine, The Ohio State University, Columbus, OH 43205, USA.
Zongdi FengCenter for Vaccines and Immunity, Nationwide Children's Hospital, USA; College of Medicine, The Ohio State University, Columbus, OH 43205, USA.
Stanley M LemonDepartment of Medicine, Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: smlemon@med.unc.edu.
Nationwide Children's Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Proteomics Pathway DiscoveryU19AI109965 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TING, JENNY P · 2014 to 2018
$14.9M
Membrane Hijacking: Biogenesis and Fate of Quasi-Enveloped HepatovirusR01AI103083 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEMON, STANLEY M. · 2012 to 2021
$4.0M
NIAID NIH HHS R01 AI103083NIAID NIH HHS U19 AI109965NIAID NIH HHS U19-AI109965
6 · The paper itself

Abstract

There is renewed interest in hepatitis A virus (HAV) pathogenesis and immunity after 2-3 decades of limited progress. From a public health perspective, the average age at infection has increased in developing countries, resulting in more severe hepatitis that is poorly understood mechanistically. More fundamentally, there is interest in comparing immunity to HAV and hepatitis C virus (HCV): small, positive-strand RNA viruses with very different infection outcomes. Here, we review evidence that circulating HAV virions are cloaked in membranes, with consequences for induction of innate immunity and antibody-mediated neutralization. We also consider the contribution of CD4+ helper versus CD8+ cytotoxic T cells to antiviral immunity and liver injury, and present a model of non-cytotoxic immune control of HAV infection.

Indexed as

Immunity, InnateAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHepatitis AHepatitis A virusHumansAntibodies, NeutralizingAntibodies, Viral

Identifiers

PMID25617494
PMCPMC4456347
OpenAlexW1992311282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.